Fig. 4
Effect of GSK-J4 treatment on a subcutaneous xenograft mouse model of H19 silenced PC-3M-luc2 cells. (A) Sequential in vivo imaging of tumor growth post subcutaneous injection of siH19 and control Vector cells in NOD/SCID mice treated with GSK-J4 (J4) or vehicle (DMSO). Panels depict a representative mouse from each group. (B) Tumor growth was measured as photons/sec in the region of interest (ROI). Data plotted as fold change vs. day 0 represent mean +/- SEM of 8 mice/group. *P < 0.05 vs. Vector + DMSO; $ <0.05 vs. siH19 + J4. (C) Ex vivo photos of representative solid tumors on the day of the explant. (D) Tumor volume was evaluated by caliper measurements at the different time points and calculated as follows: V (mm3) = (W2 × L)/2. Data represent mean +/- SEM of 8 mice/group. *P < 0.05 vs. Vector + DMSO;$ <0.05 vs. siH19 + J4 (E) CDH1 and ITGB4 mRNA analyzed by qPCR in tumor samples. Data, represented as fold change vs. mean Vector + DMSO, represent the mean +/-SEM of 8 mice/group (white dots). *P < 0.05. (F) Representative western blot and relative densitometric analysis for bcl-2 in tumor samples. β-actin was used as a loading control. Molecular weight marker is indicated. Data plotted as fold change vs. mean Vector + DMSO represent mean ± SEM of 5-6 mice/group (white dots). *P < 0.05